Keyword Analysis & Research: atara biotherapeutics
Keyword Research: People who searched atara biotherapeutics also searched
Search Results related to atara biotherapeutics on Search Engine
-
Allogeneic T-cell Immunotherapy Company - Atara Biotherapeutics
https://www.atarabio.com/
WEBFeb 29, 2024 · Explore patient stories, our clinical studies, or visit our investor hub for more information. Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune, and viral diseases.
DA: 51 PA: 69 MOZ Rank: 70
-
Atara Biotherapeutics, Inc. (ATRA) - Yahoo Finance
https://finance.yahoo.com/quote/ATRA
WEBAtara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the...
DA: 88 PA: 61 MOZ Rank: 98
-
About - T-Cell Immunotherapy Technology Platform - Atara Biotherapeutics
https://www.atarabio.com/company/
WEBLearn how we align our work with our mission, culture, and core values every day. Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune, and viral diseases.
DA: 13 PA: 23 MOZ Rank: 73
-
Atara Biotherapeutics (ATRA)
https://investors.atarabio.com/
WEBDec 31, 2023 · Latest News. View All News. Apr 5, 2024. Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635 (c) (4) View Press Release. Mar 28, 2024. Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress. View Press Release.
DA: 16 PA: 65 MOZ Rank: 75
-
T-cell immunotherapies for cancer, autoimmune ... - Atara Biotherapeutics
https://www.atarabio.com/pipeline/
WEBAtara Biotherapeutics’s robust, late-stage pipeline features a host of potentially transformative T-cell immunotherapies for cancer, autoimmune and viral diseases.
DA: 1 PA: 53 MOZ Rank: 87
-
Atara Biotherapeutics Announces Fourth Quarter and Full Year …
https://finance.yahoo.com/news/atara-biotherapeutics-announces-fourth-quarter-123000879.html
WEBMar 28, 2024 · THOUSAND OAKS, Calif., March 28, 2024--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform...
DA: 34 PA: 37 MOZ Rank: 33
-
Atara Biotherapeutics and Pierre Fabre Laboratories Announce
https://investors.atarabio.com/news-events/press-releases/detail/340/atara-biotherapeutics-and-pierre-fabre-laboratories
WEBJan 31, 2024 · In December 2023, Atara announced the closing of the expanded global partnership with Pierre Fabre Laboratories for the U.S. and remaining global commercial markets for tabelecleucel, building on an initial partnership covering Europe, Middle East, Africa, and other select emerging markets.
DA: 41 PA: 9 MOZ Rank: 13
-
Atara Biotherapeutics Announces Primary Analysis Data from …
https://www.businesswire.com/news/home/20231108902565/en/Atara-Biotherapeutics-Announces-Primary-Analysis-Data-from-Phase-2-EMBOLD-Clinical-Trial-of-ATA188-in-Non-Active-Progressive-Multiple-Sclerosis
WEBNov 8, 2023 · THOUSAND OAKS, Calif.-- ( BUSINESS WIRE )-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell...
DA: 47 PA: 64 MOZ Rank: 94
-
Tab-cel - Atara Biotherapeutics
https://www.atarabio.com/pipeline/tabelecleucel/
WEBATA3431. ATA188. Pipeline. Tabelecleucel (tab-cel ® ) First-in-class allogeneic T-cell therapy. With European Commission marketing authorization, Atara is the first company to ever receive approval for an allogeneic T-cell immunotherapy.*
DA: 74 PA: 12 MOZ Rank: 100
-
Technology - Atara Biotherapeutics
https://www.atarabio.com/science-and-technology/
WEBLearn more about our ongoing studies. As a leading allogeneic T-cell immunotherapy company, Atara is pioneering the development of transformative therapies for patients with serious diseases by leveraging our novel allogeneic Epstein Barr virus (EBV) T …
DA: 88 PA: 49 MOZ Rank: 82